These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 12872001)

  • 1. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
    Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans.
    Morelli F; Romeo M; Barzago MM; Bolis M; Mattioni D; Rossi G; Tagliavini F; Bastone A; Salmona M; Diomede L
    Neurobiol Dis; 2018 Sep; 117():226-234. PubMed ID: 29936232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans.
    Kraemer BC; Burgess JK; Chen JH; Thomas JH; Schellenberg GD
    Hum Mol Genet; 2006 May; 15(9):1483-96. PubMed ID: 16600994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive neurodegeneration in C. elegans model of tauopathy.
    Miyasaka T; Ding Z; Gengyo-Ando K; Oue M; Yamaguchi H; Mitani S; Ihara Y
    Neurobiol Dis; 2005 Nov; 20(2):372-83. PubMed ID: 16242642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.
    Zhang B; Higuchi M; Yoshiyama Y; Ishihara T; Forman MS; Martinez D; Joyce S; Trojanowski JQ; Lee VM
    J Neurosci; 2004 May; 24(19):4657-67. PubMed ID: 15140937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies.
    Higuchi M; Zhang B; Forman MS; Yoshiyama Y; Trojanowski JQ; Lee VM
    J Neurosci; 2005 Oct; 25(41):9434-43. PubMed ID: 16221853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations
    Bardai FH; Wang L; Mutreja Y; Yenjerla M; Gamblin TC; Feany MB
    J Neurosci; 2018 Jan; 38(1):108-119. PubMed ID: 29138281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau mutant A152T, a risk factor for FTD/PSP, induces neuronal dysfunction and reduced lifespan independently of aggregation in a C. elegans Tauopathy model.
    Pir GJ; Choudhary B; Mandelkow E; Mandelkow EM
    Mol Neurodegener; 2016 Apr; 11():33. PubMed ID: 27118310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodegenerative tauopathy in the worm.
    Goedert M
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9653-5. PubMed ID: 12913116
    [No Abstract]   [Full Text] [Related]  

  • 11. Transgenic animal models of tauopathies.
    Lee VM; Kenyon TK; Trojanowski JQ
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):251-9. PubMed ID: 15615643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic nervous system degeneration in a C. elegans Tau
    Choudhary B; Mandelkow E; Mandelkow EM; Pir GJ
    Neurobiol Dis; 2018 Sep; 117():189-202. PubMed ID: 29894752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model.
    Guha S; Fischer S; Johnson GVW; Nehrke K
    Mol Neurodegener; 2020 Nov; 15(1):65. PubMed ID: 33168053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin improves tau-induced neuronal dysfunction of nematodes.
    Miyasaka T; Xie C; Yoshimura S; Shinzaki Y; Yoshina S; Kage-Nakadai E; Mitani S; Ihara Y
    Neurobiol Aging; 2016 Mar; 39():69-81. PubMed ID: 26923403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
    Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
    Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration.
    Forman MS; Lal D; Zhang B; Dabir DV; Swanson E; Lee VM; Trojanowski JQ
    J Neurosci; 2005 Apr; 25(14):3539-50. PubMed ID: 15814784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
    Strang KH; Golde TE; Giasson BI
    Lab Invest; 2019 Jul; 99(7):912-928. PubMed ID: 30742061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.
    Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW
    J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) due to microtubule-associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy.
    Tacik P; Sanchez-Contreras M; DeTure M; Murray ME; Rademakers R; Ross OA; Wszolek ZK; Parisi JE; Knopman DS; Petersen RC; Dickson DW
    Neuropathol Appl Neurobiol; 2017 Apr; 43(3):200-214. PubMed ID: 27859539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.